GRI Bio (GRI) Income from Continuing Operations (2020 - 2026)
GRI Bio (GRI) posted quarterly Income from Continuing Operations of 2003000.0 for Q1 2026, up 34.35% year-over-year from 1490888.75 in Q1 2025, and up 91.14% quarter-over-quarter from 22615000.0 in Q4 2025.
GRI Bio (GRI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
GRI Bio's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 2003000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 34.35% year-over-year to 2003000.0; the TTM figure through Mar 2026 stood at 30986000.0 (down 18.83% YoY), while the FY2025 annual figure was 31928000.0, down 28.13% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2003000.0, up from 22615000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 187000.0 in Q3 2022, with the low at 22615000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 2644000.0 (2022), against an average of 5473411.76.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 91.82% in 2022, then tumbled 3039.68% in 2023.
- GRI Bio's Income from Continuing Operations stood at 5163000.0 in 2022, then tumbled by 220.49% to 16547000.0 in 2023, then dropped by 12.64% to 18638000.0 in 2024, then slipped by 21.34% to 22615000.0 in 2025, then surged by 91.14% to 2003000.0 in 2026.
- Business Quant data shows GRI's Income from Continuing Operations at 2003000.0 in Q1 2026, 22615000.0 in Q4 2025, and 3471000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | -1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.00 Mn |
| Dec 31, 2025 | -22.62 Mn |
| Sep 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -3.05 Mn |
| Dec 31, 2024 | -18.64 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -2.26 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -2.44 Mn |
| Jun 30, 2023 | -5.93 Mn |
| Mar 31, 2023 | -988,000.00 |
| Dec 31, 2022 | -5.16 Mn |
| Sep 30, 2022 | -187,000.00 |
| Jun 30, 2022 | -189,000.00 |
| Mar 31, 2022 | -2.64 Mn |
| Dec 31, 2021 | -10.11 Mn |
| Sep 30, 2021 | -1.26 Mn |
| Jun 30, 2021 | -2.31 Mn |